

IN THE CLAIMS

Please cancel claims 1-20 without prejudice and add the following new claims. Provided below is a listing of the pending claims:

Claims 1-20 (canceled)

21. (New) A pharmaceutical composition comprising R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(-) stereoisomer; a therapeutically effective amount of at least one other therapeutic agent; and a pharmaceutically acceptable carrier.

22. (New) The pharmaceutical composition of claim 21, wherein the other therapeutic agent is selected from fluoxetine or the R or S isomer thereof, norcisapride or the (+) or (-) stereoisomer thereof, ubidecarenone, dipyrámole, pilocarpine or a stereoisomer thereof, primidone or the R or S stereoisomer thereof, or orphenadrine citrate.

23. (New) The pharmaceutical composition of claim 21, wherein the R(+)ondansetron, or a pharmaceutically acceptable salt thereof, is greater than approximately 90% by weight of the total ondansetron.

24. (New) The composition of claim 21, comprising R(+)ondansetron hydrochloride.

25. (New) The composition of claim 21, wherein the amount of R(+)ondansetron, or a pharmaceutically acceptable salt thereof, ranges from about 0.001 mg to about 35 mg.

26. (New) The composition of claim 21, adapted for oral administration.

27. (New) The composition of claim 21, adapted for parenteral administration.

28. (New) The composition of claim 21, wherein the other therapeutic agent is fluoxetine or the R or S isomer thereof.

29. (New) The composition of claim 21, wherein the other therapeutic agent is norcisapride or the (+) or (-) stereoisomer thereof.

30. (New) The composition of claim 21, wherein the other therapeutic agent is ubidecarenone.

31. (New) The composition of claim 21, wherein the other therapeutic agent is dipyrámole.

32. (New) The composition of claim 21, wherein the other therapeutic agent is pilocarpine or a stereoisomer thereof.

33. (New) The composition of claim 21, wherein the other therapeutic agent is primidone or the R or S stereoisomer thereof.

34. (New) The composition of claim 21, wherein the other therapeutic agent is orphenadrine citrate.